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Background: Data on the safety of selective serotonin-reuptake inhibitors (SSRIs) in pregnancy 
are inconsistent. We examined associations between SSRI use during early pregnancy and risk 
of congenital malformations in infants.
Methods: Set in Northern Denmark, our population-based prevalence study included 
216,042 women who had a live birth after the 20th week of gestation. We compared the preva-
lence of malformation in infants born to women who redeemed at least one SSRI prescrip-
tion during early pregnancy with the prevalence in infants born to women who redeemed no 
SSRI prescriptions during their pregnancies. Drug use data were extracted from prescription 
databases, while data on congenital malformations were obtained from the National Registry 
of Patients.
Results: The 2,062 women with SSRI prescriptions during early pregnancy gave birth to 
105 (5.1%) infants with malformations, while the 213,712 women with no SSRI prescrip-
tions gave birth to 7,449 (3.5%) infants with malformations. SSRI use was associated with an 
increased risk of malformations overall (odds ratio [OR] = 1.3; 95% confidence interval (CI): 
1.1–1.6) and cardiac malformations (OR = 1.7; 95% CI: 1.1–2.5). For specific SSRIs, we found 
an increased risk for septal defects associated with sertraline.
Conclusions: We found little overall association between use of SSRIs during pregnancy and 
congenital malformations, but our findings suggest an association between maternal SSRI use 
in early pregnancy and cardiac malformations which could be causal.
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Introduction
Selective serotonin-reuptake inhibitors (SSRIs), the first-line pharmacotherapy 
for depression, represent the most frequently used antidepressant among pregnant 
women.1–3 Between 2% and 13% of all pregnant women are treated with 
  antidepressants1–3 and use of SSRIs during pregnancy has increased two- to fourfold 
in western populations during the last decade.2–4
SSRIs readily cross the placenta5,6 and concerns have been raised about their safety 
in pregnancy, including the risk of low birth weight, prematurity, low Apgar score, 
and persistent pulmonary hypertension in the newborn.7 Maternal SSRI use during 
pregnancy also has been associated with an almost twofold increased risk of congeni-
tal malformations overall,8–10 but existing studies have yielded divergent results.8–17 
Furthermore, maternal SSRI use have been associated with the risk of congenital 
cardiac malformations in some8,12,16,18–21 but not all studies,11,22 and with the risk of 
omphalocele, anencephaly, and craniosynostosis.22 The discrepancies may stem from Clinical Epidemiology 2010:2 30
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  methodological differences. For instance some studies are 
studies based on data from Teratogen Information Service 
centers, which offer advice to women, who request counsel-
ling about the teratogenic potential of SSRIs.13,15,21 These 
women are thus included based on self-referral, which may 
threaten the validity. Others are retrospective case-control 
studies based on interviews or questionnaires with the risk 
of recall bias and skewed data due to a high proportion of 
nonresponders,19,22 and some are based on linkage between 
large administrative registers.8–12,20 Since specific SSRIs 
do not share chemical structures and pharmacokinetic 
  properties,23 they could have different teratologic effects. 
Paroxetine has been associated with a 1.7-fold increased 
risk of cardiac malformations in a recent meta-analysis.18 
However, relatively few studies have assessed the risk of 
malformation associated with use of other specific SSRIs, 
and their results are inconsistent.12,16,19–22
Because of the increasing use of SSRI during pregnancy 
and the fact that untreated depression during pregnancy can 
have adverse effects on the mother and her child,24,25 it is 
important to clarify whether maternal SSRI use increases 
the risk of congenital malformations and to identify the 
specific SSRIs associated with the highest risk. We therefore 
updated a previous analysis9 to examine the associations 
between SSRI use during early pregnancy and overall risk of 
congenital malformations and risk of cardiac malformations 
in infants.
Methods
Setting and study population
We conducted this population-based prevalence study in a 
population of 1.6 million from Northern Denmark (approxi-
mately 31% of the Danish population). We used data from the 
counties’ computerized prescription registries during three 
time periods, corresponding to the dates of data availability in 
the counties; 1991–2007 (North Jutland County), 1996–2007 
(Aarhus County), and 1998–2007 (Ringkjøbing and Viborg 
Counties). Our study included all women in the counties who 
had a live birth after the 20th week of gestation during the 
periods covered by the prescription registries. The women 
were identified through the Danish Medical Birth Registry, 
which contains information on all births in Denmark since 
January 1973.26 The main variables in the registry include 
maternal age, parity, birth weight, gestational age, maternal 
smoking status during pregnancy, citizenship, data on 
delivery, and information on multiple pregnancy. We used 
the unique civil registration number assigned to all Danish 
residents at birth or upon immigration to link the prescription 
records with data from the Danish Medical Birth Registry 
and the National Registry of Patients.
Data on antidepressants and other drugs
The Danish National Health Service reimburses part of 
patient expenditures for numerous prescribed medicines 
including SSRIs. The four counties are served by pharmacies 
equipped with electronic accounting systems that track data 
on all prescriptions on reimbursable medicines including the 
patients’ civil registration number, type of drug prescribed 
according to the Anatomical Therapeutic Chemical (ATC) 
classification system, amount prescribed, and the date the 
drug was dispensed. All data are transferred to a research 
database at Aarhus University Hospital. In Denmark, SSRIs 
may be obtained from pharmacies only with a prescription 
from a medical doctor. ATC codes for specific SSRIs are 
citalopram (N06A B04), sertraline (N06A B06), fluvoxamine 
(N06A B08), fluoxetine (N06A B03), paroxetine (N06A 
B05), and escitalopram (N06A B10). We obtained data 
on all prescriptions for a SSRI redeemed by women in our 
study cohort from 30 days before conception until the end 
of each pregnancy.
Finally, we also retrieved data on prescriptions for 
non-SSRI antidepressants (N06AA, NO6AF, N06AG, 
N06AX) to examine the risk of congenital malformations 
after maternal use of these alternative medications. We 
excluded women who redeemed prescriptions for both a SSRI 
and a non-SSRI antidepressants in the period from 30 days 
before conception until the end of each pregnancy.
Outcome data
Data on congenital malformations were obtained from the 
National Registry of Patients. This registry, established in 
1977, includes dates of admission and discharge, surgical 
procedures performed, and up to 20 discharge diagnoses 
coded by physicians according to the International Clas-
sification of Diseases, 8th revision (ICD-8) until the end of 
1993 and 10th revision (ICD-10) thereafter. The following 
codes were used to identify malformations: malforma-
tions overall (ICD-8: 740–759, except 747.0 and ICD-10: 
Q00–Q99, except Q25.0); cardiac malformations overall 
(ICD-8: 746.0–746.6, 746.8–746.9, 747.1–747.4 and 
ICD-10: Q20.0–Q20.6, Q20.8–Q20.9, Q21.0–21.4, Q21.8–
21.9, Q22.0–22.9, Q23.0–23.9, Q24.0–24.9, Q25.1–25.9, 
Q26.0–26.4, Q26.8–26.9), and septal defects (ICD-8: 
746.2–746.4 and ICD-10: Q21.0–Q21.4, Q21.8–Q21.9). 
To standardize the period of observation, we included 
only malformations registered during the first year of life. Clinical Epidemiology 2010:2 31
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We excluded diagnoses of congenital dislocations of the hip 
(ICD-8 code 755.69 and ICD-10 codes Q65.0–65.6) and 
undescended testes (ICD-8 codes 752.10–752.11, 752.19 
and ICD-10 code Q53) due to the poor validity of these 
  diagnoses.27 We also excluded women who had a multiple 
birth or whose infants had chromosomal defects. The follow-
ing procedure codes were used to identify infants, who had 
had heart surgery, or catheter-based therapeutic interventions 
performed during their first year of life: 30500–32990 and 
KFA–KFX.
Data on potential confounders
Because diabetes and use of antiepileptics have been associ-
ated with an increased risk of congenital malformations,28,29 
we excluded women who used antiepileptics (ATC code 
N03A) during the first trimester of pregnancy or 90 days 
before conception or who used antidiabetic drugs (ATC 
code A10) at any time before conception or during the entire 
pregnancy. Data on other potential confounders, including 
maternal age, birth order, and maternal smoking status, were 
obtained from the Danish Medical Birth Registry.
Statistical analysis
We used logistic regression to compute crude and adjusted 
prevalence odds ratios (ORs) with associated 95% confi-
dence intervals (CIs) for congenital malformations overall 
among women who redeemed any SSRI prescription in early 
pregnancy (from 30 days before conception until the end of 
the first trimester) and among women who redeemed a SSRI 
prescription in the second or third month of pregnancy, which 
is the most critical period for development of malforma-
tions. The comparison group consisted of women who did 
not redeem a SSRI prescription in the period from 30 days 
before conception to the end of pregnancy. We adjusted for 
maternal smoking during pregnancy (smoker, nonsmoker), 
birth order (1, >1), maternal age (as a continuous vari-
able), and birth year (1991–1994, 1995–1998, 1999–2002, 
2003–2007).
We examined four categories of malformations: 
  malformations  overall,  noncardiac  malformations, 
cardiac malformations, and septal defects diagnosed within 
the infant’s first year of life. We then computed ORs for 
these outcomes associated with SSRI use overall, with use of 
individual SSRIs, and with use of non-SSRI antidepressants 
in early pregnancy. Because the occurrence of a malformation 
may change prescription practice in a subsequent pregnancy, 
we also examined the association between SSRI use and 
malformations among firstborn infants only.
In a separate analysis, we extended the follow-up-period 
and examined the association between use of SSRIs and 
cardiac malformations diagnosed within the infants first 
three years of life.
We addressed whether a possible association between 
SSRI use and congential malformations could be explained 
by the underlying disease for which SSRIs were prescribed 
or by disease-related behavioral factors. In subanalyses we 
examined the association between SSRI exposure and con-
genital malformations in women who redeemed an SSRI 
prescription six months before conception up to 30 days 
before conception, and in women who redeemed an SSRI 
prescription in their second or third trimester. The compari-
son group for these analyses consisted of women who did not 
redeem any SSRI prescriptions before giving birth.
Finally, to address whether any association between 
SSRI use and cardiac malformations could be explained by 
increased surveillance of SSRI-exposed infants, we analyzed 
the association between maternal SSRI use and risk of cardiac 
malformation restricting the outcome to infants who had 
heart surgery, or catheter-based therapeutic interventions 
performed during their first year of life.
We analyzed data using SAS software (version 9.2; 
SAS Institute, Cary, NC, USA). The Danish Registry Board 
approved the study (record no. 2002-41-1820).
Results
Descriptive data
Among the 216,042 women who had a live birth during the 
study period, a total of 2,062 (1.0%) redeemed a prescrip-
tion for an SSRI in early pregnancy (from 30 days before 
conception until the end of the first trimester) and 931 (0.4%) 
redeemed a prescription during the second or third month of 
pregnancy. Compared with women without SSRI prescrip-
tions during the entire pregnancy, those with SSRI prescrip-
tions tended to be slightly older (median age 30.5 years vs 
29.8 years) and were more likely to be smokers, and to 
have preterm delivery (defined as delivery 37 gestational 
weeks) (Table 1). The most common SSRI and combinations 
of SSRIs prescribed to women during early pregnancy are 
shown in Table 2. The women who used combinations of 
SSRI, except in four cases, redeemed the different types of 
SSRIs on different dates.
SSRI use and congenital 
malformations overall
Among the infants of the 2,062 women who redeemed 
a SSRI prescription any time during early pregnancy, Clinical Epidemiology 2010:2 32
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105 (5.1%) infants had congenital malformations compared 
with a prevalence of 3.5% among the unexposed. Among 
infants of women with SSRI prescriptions during early preg-
nancy, a total of 104 different malformation diagnoses were 
recorded, including 88 noncardiac diagnoses. The most fre-
quently recorded malformation diagnoses were atrial septal 
defect (n = 11), ventricular septal defect (n = 10), congenital 
malformation unspecified (n = 8), congenital cardiac mal-
formation, unspecified (n = 7) stenosis of pulmonary artery 
(n = 5), congenital hydronephrosis (n = 5), and plagiocephaly 
(n = 5). Other malformations had fewer than five records. 
Table 3 shows the absolute number and prevalence of infants 
with any malformation, noncardiac malformation, cardiac 
malformation, and septal heart defect according to maternal 
use of different types of antidepressants.
Redemption of any SSRI prescription in early pregnancy 
was associated with a 1.3-fold (95% CI: 1.1–1.6) increased 
risk of malformations overall (Table 4). The corresponding 
OR was 1.2 (95% CI: 0.9–1.6), when we repeated the analysis 
in firstborn infants only. For noncardiac malformations, the 
adjusted OR was 1.2 (95% CI: 1.0–1.6) (Table 4). Redemp-
tion of any SSRI prescription during the second or third 
month of pregnancy was associated with a 1.1-fold (95% CI: 
0.8–1.6) increased risk of malformations overall.
For several of the individual SSRIs we found an increased 
risk of congenital malformations overall following use in 
early pregnancy (Table 4). However, our confidence intervals 
are wide and they all include 1.0 (Table 4).
We identified 1,226 women who redeemed SSRI pre-
scriptions from six months to 30 days before conception 
(but not during pregnancy) and 266 women who redeemed 
SSRI prescriptions during their second or third trimester. 
The adjusted OR for malformations overall was 1.1 (95% 
CI: 0.8–1.4) for SSRI use in the period from six months to 
Table 1 Characteristics of women with and without prescriptions for selective serotonin-reuptake inhibitors (SSRIs)
SSRI prescriptions redeemed No prescriptions for SSRIs 
during the entire pregnancy 
or 30 days before conception 
No (%) (n = 213,712)
Within first trimester or 30 days 
before conception No (%) 
(n = 2,062)
Within second or third month 
after conception No (%) (n = 931)
Maternal age (years)
  19 27 (1.3) 7 (0.8) 3,074 (1.4)
  20–24 265 (12.9) 113 (12.1) 26,426 (12.4)
  25–29 660 (32.0) 284 (30.5) 80,649 (37.7)
  30–34 676 (32.8) 315 (33.8) 72,857 (34.1)
  35 434 (21.0) 212 (22.8) 30,706 (14.4)
Parity
  1 872 (42.3) 406 (43.6) 88,980 (41.6)
  1 1,190 (57.7) 525 (56.4) 124,732 (58.4)
Birth year
  1991–1994 4 (0.2) 2 (0.2) 17,501 (8.2)
  1995–1998 112 (5.4) 21 (2.3) 38,570 (18.0)
  1999–2002 509 (24.7) 165 (17.7) 71,863 (33.6)
  2003–2007 1,437 (69.7) 743 (79.8) 85,778 (40.1)
Maternal smoking status
  No 1,263 (61.3) 602 (64.7) 164,771 (77.1)
  Yes 739 (35.8) 296 (31.8) 43,981 (20.6)
  Missing 60 (2.9) 33 (3.5) 4,960 (2.3)
Infants with congenital 
malformations
105 (5.1) 42 (4.5) 7,449 (3.5)
Infants with congenital 
cardiac malformations
26 (1.3) 11 (1.2) 1,403 (0.7)
Gestational age
  31 20 (1.0) 10 (1.1) 1,439 (0.7)
  32–36 122 (5.9) 65 (7.0) 8,675 (4.1)
  37 1,920 (93.1) 856 (91.9) 203,598 (95.3)Clinical Epidemiology 2010:2 33
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30 days before conception and 1.0 (95% CI: 0.5–1.9) for use 
in the second or third trimester. We also found no increased 
risk associated with use of non-SSRI antidepressants in early 
pregnancy (OR = 0.5; 95% CI: 0.2–1.1).
SSRI use and congenital cardiac 
malformations
The prevalence of congenital cardiac malformations recorded 
during the first year of life was 1.3% among infants born 
to mothers who redeemed a SSRI prescription in early 
pregnancy and 0.7% among infants born to unexposed 
mothers (Table 1). The adjusted OR for congenital cardiac 
malformations associated with SSRI use in early pregnancy 
overall was 1.7 (95% CI: 1.1–2.5) (Table 4). When we 
restricted the analysis to firstborn infants only, the adjusted 
OR was 1.5 (95% CI: 0.8–2.9). Also, when we extended the 
follow-up period and examined the risk of cardiac malforma-
tions diagnosed within the first three years of life, the OR 
increased similarly (OR = 1.5; 95% CI: 1.0–2.3).
In total, 362 infants had a diagnosis of cardiac malfor-
mations and heart surgery, or catheter-based therapeutic 
interventions performed during their first year of life; of 
these, nine were infants born to mothers who redeemed a 
SSRI prescription in early pregnancy. After we restricted the 
outcome to infants who had cardiac malformations, heart sur-
gery, or catheter-based therapeutic interventions performed, 
the adjusted OR was 2.3 (95% CI: 1.1–4.6).
Except for paroxetine, use of individual SSRIs were all 
associated with increased risks of cardiac malformations but 
our estimates were imprecise (Table 4). Notably, sertraline was 
associated with a threefold increased risk of cardiac malforma-
tions (OR = 3.0; 95% CI: 1.4–6.4). The associations between 
SSRI use overall and septal defects was 1.4 (95% CI: 0.8–2.3). 
In the analysis restricted to septal defects among firstborn infants 
only, the OR was 1.0 (95% CI: 0.4–2.3). Among the individual 
SSRIs, we found increased risk for septal defects associated 
with sertraline (OR = 3.3; 95% CI: 1.5–7.5) (Table 4).
Discussion
In this population-based study of more than 2,000 exposed 
pregnancies, we found that overall maternal use of SSRIs 
in early pregnancy was associated with a 1.7-fold increased 
risk of congenital cardiac malformations. Septal heart defects 
were the most frequently recorded malformations among 
infants of exposed women, with sertraline associated with 
a threefold increased risk of such defects. However, the 
absolute prevalences were small.
Table 2 Number and percent of women who redeemed one or 
more prescriptions for specific selective serotonin-reuptake inhibitors 
(SSRIs) or combinations of SSRIs during early pregnancy
Drug Number (%)
Citalopram 658 (31.9)
Fluoxetine 472 (22.9)
Sertraline 352 (17.1)
Paroxetine 297 (14.4)
Escitalopram 88 (4.3)
Fluoxetine + citalopram 68 (3.3)
Fluoxetine + paroxetine 33 (1.6)
Citalopram + sertraline 22 (1.0)
Fluoxetine + sertraline 22 (1.0)
Fluoxetine + escitalopram 16 (0.8)
Sertraline + escitalopram 9 (0.4)
Citalopram + paroxetine 8 (0.4)
Citalopram + escitalopram 6 (0.3)
Paroxetine + sertraline 4 (0.2)
Fluvoxamine 3 (0.1)
Fluoxetine + citalopram + sertraline 2 (0.1)
Fluoxetine + sertraline + escitalopram 1 (0)
Fluoxetine + citalopram + paroxetine 1 (0)
Table 3 Number of exposed (prevalence among exposed) infants with any malformation, noncardiac malformation, cardiac malformation, 
and septal heart defects according to maternal use of different types of antidepressantsa
  Total number 
of exposed
Any malformation 
n (%)
Noncardiac 
malformations n (%)
Cardiac 
malformations n (%)
Septal heart 
defects n (%)
Any SSRIb 2,062 105 (5.1) 79 (3.8) 26 (1.3) 18 (0.9)
Fluoxetine only 472 22 (4.7) 16 (3.4) 6 (1.3) 4 (0.9)
Sertraline only 352 19 (5.4) 12 (3.4) 7 (2.0) 6 (1.7)
Paroxetine only 297 11 (3.7) 10 (3.4) 1 (0.3) 1 (0.3)
Citalopram only 658 36 (5.5) 30 (4.6) 6 (0.9) 2 (0.3)
Escitalopram only 88 8 (9.1) 5 (5.7) 3 (3.4) 3 (3.4)
Non-SSRI 
antidepressants
358 6 (1.7) 6 (1.7) 0 (0.0) 0 (0.0)
Notes: aThree women used fluvoxamine only and their infants had no malformations registered; bExclusive combinations with non-SSRI antidepressants.Clinical Epidemiology 2010:2 34
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Our finding of an elevated risk of septal defects 
  associated with sertraline use agrees with two recent stud-
ies.16,19 In a US case-control study based on data from the 
Slone Epidemiology Center Birth Defects Study, Louik and 
colleagues found a twofold increased risk of septal defects 
(95% CI: 1.2–4.0) associated with first-trimester use of 
sertraline but not with other specific SSRIs.19 Exposure 
information was collected through interviews of mothers 
with the attendant risk of recall bias. Recently, Petersen 
and colleagues reported increased risk of septal defects 
associated with maternal use of sertraline (OR = 3.3; 95% 
CI: 1.2–8.8) and citalopram (OR = 2.5; 95% CI: 1.0–6.1) in 
a Danish cohort study.16 The authors also found a positive 
but imprecisely measured association between flouxetine 
and septal defects (OR = 1.34; 95% CI: 0.3–5.4). The effect 
of the newer SSRI escitalopram was not examined. Our data 
are from the same registers as those used by Pedersen and 
colleagues,16 however, the study by Pedersen and colleagues 
was based on nationwide registries and included children 
born in Denmark between 1996 and 2003.
In contrast with a meta-analyses based on pre-2006 
research,18 we found no association between maternal par-
oxetine use and cardiac malformations. However, the wide 
CIs of our paroxetine estimates suggest that this finding could 
be due to chance.
We found a slightly increased risk of malformations over-
all associated with SSRI use. However, the malformations 
encompassed 104 different hospital diagnoses, which sug-
gests that the increased risk of malformations overall could be 
explained by detection bias rather than a causal association. 
Most previous studies did not find that maternal SSRI use 
increased the overall risk of congenital malformations.11–17
The strengths of our study include its population-
based design, adjustment for important confounders, 
and complete follow-up for congenital malformations. 
Use of routinely recorded health care data collected 
independently of the study hypothesis reduced the risk 
of information bias.
The validity of our estimates is dependent on the quality 
of diagnoses of congenital malformations and on the quality 
of data on SSRI exposure. Despite inevitable coding errors, 
in Denmark the estimated positive predictive value is 88% 
(95% CI: 86%–91%) for hospital diagnoses of congenital 
malformations overall27 and 89% (95% CI: 86%–92%) for 
cardiac malformations.30 Any coding errors affecting malfor-
mation diagnoses are unlikely to be related to prescribing of 
SSRIs and would therefore lead to an underestimation of the 
relative risk. However, detection bias, in which the mothers 
being treated for depression are more likely to receive or 
seek out more comprehensive prenatal and postnatal testing 
of their infants may lead to more complete detection and 
registration of the less severe congenital malformations.31 
Moreover, infants born of women using SSRI have an 
increased risk of neonatal distress,7 which may lead to neo-
natal hospitalization and thus increase the risk of detection 
of mild cardiac defects that may otherwise remain unnoticed 
until later in life. Such bias would cause overestimation of 
the relative risk associated with the use of SSRIs. However, 
when we restricted the analysis to the more severe cases, 
ie, infants who had heart surgery/catheter-based thera-
peutic interventions performed, we also found a positive 
  association.
Another concern is that we used population-based data on 
malformations recorded during the first year of life, but did 
not consider malformations leading to a miscarriage or to an 
elective abortion after prenatal diagnosis.9 However, if SSRI 
use increased the risk of malformation-related miscarriage/
elective abortion, the association between SSRI use and risk 
Table 4 Adjusted odds ratios and 95% confidence intervals for overall and individual (SSRIs)a in relation to congenital malformations
Outcome  Any SSRIb  Fluoxetine 
only
Sertraline 
only
Paroxetine 
only
Citalopram 
only
Escitalopram 
only
Non-SSRI 
  antidepressant
Adjusted odds ratio (95% confidence interval)
Any malformation 1.3 (1.1–1.6) 1.3 (0.8–2.0) 1.4 (0.9–2.3) 1.1 (0.6–1.9) 1.4 (1.0–2.0) 2.3 (1.0–4.9) 0.5 (0.2–1.1)
Noncardiac 
malformations
1.2 (1.0–1.6) 1.1 (0.7–1.9) 1.0 (0.5–1.9) 1.2 (0.6–2.2) 1.4 (1.0–2.1) 2.0 (0.8–4.9) 0.6 (0.3–1.3)
Cardiac 
malformations
1.7 (1.1–2.5) 1.9 (0.8–4.3) 3.0 (1.4–6.4) 0.5 (0.1–3.6) 1.1 (0.5–2.7) 3.3 (0.8–13.4) –
Septal heart 
defects
1.4 (0.8–2.3) 1.6 (0.6–4.4) 3.3 (1.5–7.5) 0.7 (0.1–4.6) 0.3 (0.0–2.1) 4.2 (1.0–17.1) –
Notes: Adjusted for maternal smoking status, maternal age, birth order, and birth year. aThree women used fluvoxamine only and their infants had no malformations registered; 
bExclusive combinations with non-SSRI antidepressants.
Abbreviation: SSRI, selective serotonin-reuptake inhibitor.Clinical Epidemiology 2010:2 35
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of malformations would have been underestimated and thus 
would not alter our conclusions.
Another issue is that redemption of SSRI prescriptions is 
an imperfect surrogate for SSRI use and we lacked specific 
information on compliance. We assume high compliance 
as the prescriptions were picked up at the pharmacy and 
paid for in part by the patient. Still, we do not know if 
the women actually took the SSRIs. Nevertheless, such 
misclassification of SSRI use would likely bias the results 
toward the null.
Yet another concern is that our exposure window was 
wide and we did not know the exact exposure time. We 
therefore conducted an analysis for women who redeemed 
prescriptions during the second and third month of preg-
nancy, when organogenesis mainly occurs.9 Restricting the 
exposure period to this time interval did not appreciably 
change the estimates for SSRI use overall.
As well, we cannot exclude the possibility that increased 
risk of congenital malformations is caused by the disease 
underlying SSRI use or by other disease-related factors, rather 
than by SSRI use itself.9 Nevertheless, we found no increased 
risk of congenital malformations overall among women using 
other antidepressants, among previous SSRI users, or among 
women exposed to SSRIs during late pregnancy.
The higher risk estimates associated with use of specific 
SSRIs could be due to chance or confounding by indication, 
if these drugs were prescribed to women with more severe 
depression. In a meta-analysis of 117 randomized controlled 
trials conducted from 1991 to 2007,32 sertraline and escitalo-
pram were found to be more efficacious than fluoxetine in 
terms of response. These drugs may be prescribed more fre-
quently to women whose severe depression requires a rapid 
treatment response. However, like most previous studies on 
this topic, we were unable to control for maternal disease type 
and severity. Finally, despite the relative large size of our 
study overall, we had limited power to evaluate associations 
between specific SSRIs and specific congenital malformation 
such as anencephaly, omphalocele, and craniosynostosis.
In conclusion, we found little overall association between 
use of SSRIs during pregnancy and congenital malforma-
tions, but our findings suggest an association between mater-
nal SSRI use in early pregnancy and cardiac malformations 
which could be causal.
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